19
Participants
Start Date
September 30, 2012
Primary Completion Date
February 29, 2016
Study Completion Date
November 30, 2016
Dovitinib
"* Study treatment: TKI258 single agent on a 5 days-on/2 days-off schedule~* Study drug: TKI258 capsule~* Dose: 500mg p.o. qd~* Every 3 weeks"
Asan Medical Center, Seoul
Lead Sponsor
Collaborators (1)
Novartis
INDUSTRY
Asan Medical Center
OTHER